Active Ingredient History

  • Now
Quizartinib (AC220) is a small molecule receptor tyrosine kinase inhibitor, originally from Ambit Biosciences and later acquired by Daiichi Sankyo, that is currently under development for the treatment of acute myeloid leukaemia. Quizartinib is sold under the brand name Vanflyta in Japan. Its molecular target is FLT3, also known as CD135 which is a proto-oncogene.   Wikipedia

  • SMILES: CC(C)(C)c1onc(NC(=O)Nc2ccc(cc2)c3cn4c5ccc(OCCN6CCOCC6)cc5sc4n3)c1
  • Mol. Mass: 560.68
  • ALogP: 5.86
  • ChEMBL Molecules:
More Chemistry
ac010220 | ac010220.2hcl | ac220 | ac-220 | ac220 compound | asp-2689 | quizartinib | quizartinib dihydrochloride


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue